ATE223221T1 - Lösliche arzneizusammensetzungen enthaltend 2- chloro-2'-deoxyadenosine - Google Patents

Lösliche arzneizusammensetzungen enthaltend 2- chloro-2'-deoxyadenosine

Info

Publication number
ATE223221T1
ATE223221T1 AT95943134T AT95943134T ATE223221T1 AT E223221 T1 ATE223221 T1 AT E223221T1 AT 95943134 T AT95943134 T AT 95943134T AT 95943134 T AT95943134 T AT 95943134T AT E223221 T1 ATE223221 T1 AT E223221T1
Authority
AT
Austria
Prior art keywords
deoxyadenosine
chloro
compositions containing
medicinal compositions
soluble medicinal
Prior art date
Application number
AT95943134T
Other languages
English (en)
Inventor
Michael Bornstein
Rosemary Rozman
Kevin Francis Long
George Kaon Wong
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Application granted granted Critical
Publication of ATE223221T1 publication Critical patent/ATE223221T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT95943134T 1994-12-22 1995-12-15 Lösliche arzneizusammensetzungen enthaltend 2- chloro-2'-deoxyadenosine ATE223221T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36208394A 1994-12-22 1994-12-22
PCT/US1995/016418 WO1996019230A1 (en) 1994-12-22 1995-12-15 Soluble 2-chloro-2'-deoxyadenosine formulations

Publications (1)

Publication Number Publication Date
ATE223221T1 true ATE223221T1 (de) 2002-09-15

Family

ID=23424634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95943134T ATE223221T1 (de) 1994-12-22 1995-12-15 Lösliche arzneizusammensetzungen enthaltend 2- chloro-2'-deoxyadenosine

Country Status (15)

Country Link
US (1) US5681822A (de)
EP (1) EP0801571B1 (de)
JP (1) JPH10512549A (de)
AT (1) ATE223221T1 (de)
CA (1) CA2208484C (de)
CZ (1) CZ194297A3 (de)
DE (1) DE69528080T2 (de)
DK (1) DK0801571T3 (de)
ES (1) ES2182920T3 (de)
HU (1) HUT77928A (de)
IL (1) IL116469A0 (de)
PL (1) PL321431A1 (de)
PT (1) PT801571E (de)
WO (1) WO1996019230A1 (de)
ZA (1) ZA9510924B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
MXPA05010635A (es) * 2003-04-02 2005-12-12 Ares Trading Sa Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
FR2873695A1 (fr) * 2004-07-30 2006-02-03 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
EP2343074A1 (de) 2009-12-23 2011-07-13 Merck Serono S.A. Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
CN111356460A (zh) 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
US20240077481A1 (en) 2021-03-03 2024-03-07 Ares Trading S.A. Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4719295A (en) * 1985-12-31 1988-01-12 Warner-Lambert Company Compound 2-iodo-2'-deoxyadenosine
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4908441A (en) * 1988-07-19 1990-03-13 Warner-Lambert Company Deoxyadenosine compounds and methods of making and using the same
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
EP0642347A4 (de) * 1992-05-19 1997-06-18 Scripps Research Inst Verwendung von 2-halo-adeninderivaten als therapeutische wirkstoffe gegen chronisch-myeloische leukämie.

Also Published As

Publication number Publication date
DK0801571T3 (da) 2003-01-06
US5681822A (en) 1997-10-28
ES2182920T3 (es) 2003-03-16
EP0801571B1 (de) 2002-09-04
CZ194297A3 (en) 1997-10-15
WO1996019230A1 (en) 1996-06-27
EP0801571A1 (de) 1997-10-22
DE69528080T2 (de) 2003-06-05
IL116469A0 (en) 1996-03-31
JPH10512549A (ja) 1998-12-02
HUT77928A (hu) 1998-11-30
PT801571E (pt) 2002-12-31
CA2208484C (en) 2008-09-23
DE69528080D1 (de) 2002-10-10
PL321431A1 (en) 1997-12-08
CA2208484A1 (en) 1996-06-27
ZA9510924B (en) 1997-06-23

Similar Documents

Publication Publication Date Title
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
ZA9510865B (en) Stable 2-chloro-2'-deoxyadenosine formulations
LT2001041A (en) Stable liquid formulations of botulinum toxin
DE69620877D1 (de) Arzneimittelformulierungen für il-12
WO1995017156A3 (en) Ethanol substitutes
CA2151774A1 (en) Skin Disinfecting Formulations
ES2145836T3 (es) Copolimeros elastomericos termoplasticos injertados de silicona, y composiciones que los contienen para el cuidado del pelo y la piel.
EP0776191A4 (de) Verfahren zur verabreichung von materialien in die haut, und dabei verwendete präparate
EP0727982A4 (de) Propylenglykolstearat-vesikel
ATE293434T1 (de) Pharmazeutische zusammensetzungen welche kukui nuss öl enthalten
ATE275974T1 (de) Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d
ATE223221T1 (de) Lösliche arzneizusammensetzungen enthaltend 2- chloro-2'-deoxyadenosine
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
DK1124577T3 (da) Anvendelse af et enterobakterielt OmpA-protein til specifik måling til antigenpræsenterende celler
JPS5750914A (en) Betamethasone external pharmaceutical
JO1907B1 (en) Dissolved compounds of 2-chloro-2-dioxin adenosine
JO1908B1 (en) Static compounds of 2-chloro-2-dioxin adenosine
CA2208241A1 (en) Stable solutions of 2-chloro-2'-deoxyadenosine formulations
IT1254452B (it) N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli
GT199600070A (es) Composicion de gel cosmetica teniendo irritacion de la piel reducida.
SI1228757T1 (en) Stable pharmaceutical solutions of nimesulide
IT1273460B (it) Formulazioni farmaceutiche ad azione antivirale per uso topico

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification